Table 4. Incidence rates of statistically significant mutations and biomarkers in local versus metastatic locations.
| Alteration | Test | Metastatic incidence (%) | Metastatic incidence ratio | Local incidence (%) | Local incidence ratio | P value |
|---|---|---|---|---|---|---|
| Immune | ||||||
| PD-1 | IHC | 35.29 | 6/17 | 80.85 | 38/47 | 0.0005 |
| SMAD pathway | ||||||
| SMAD2 | CNA | 4.35 | 3/69 | 0 | 0/137 | 0.0365 |
| PI3K related kinases | ||||||
| PTEN | NGS | 4.55 | 3/66 | 13.77 | 19/138 | 0.0470 |
| Other | ||||||
| FGFR3 | NGS | 6.85 | 5/73 | 0 | 0/141 | 0.0042 |
IHC, immunohistochemistry; CNA, copy number alteration; NGS, next-generation sequencing.